FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294911> ?p ?o ?g. }

• W4286294911 endingPage "TPS2693" @default.
• W4286294911 startingPage "TPS2693" @default.
• W4286294911 abstract "TPS2693 Background: M2-like macrophages are thought to promote an immunoinhibitory environment and prevent activation and proliferation of T cells, leading to resistance to checkpoint inhibitor (CPI) therapy. OR2805 is a fully human monoclonal antibody identified in a patient who had an exceptional response to CPI. OR2805 recognizes CD163, an immunosuppressive scavenger receptor highly expressed on M2 tumor-associated macrophages (TAMs). OR2805 treatment reprograms M2 macrophages to take on an immunostimulatory, M1-like phenotype. In macrophage/T cell coculture assays, OR2805 treatment relieved the suppressive effect of M2c macrophages as demonstrated by increased T-cell proliferation and stimulation of IFN-γ and perforin release. OR2805 restored the IFN-γ production of exhausted T cells and showed a synergistic effect on cocultures treated in combination with CPI. OR2805 monotherapy demonstrated significant anti-tumor activity in lung cancer xenograft models in NSG-SGM3 mice. Relieving the immune suppression of CD163-expressing TAMs by OR2805 to improve anti-tumor T-cell responses will be evaluated alone and in combination with CPI therapy. Methods: This phase 1/2, open-label, multicenter, dose-escalation/expansion study is assessing the safety, tolerability and preliminary activity of OR2805 alone and in combination with anti-PD-1 or chemotherapy in up to 325 adults (≥18 years) with histologically or cytologically confirmed metastatic or locally advanced solid tumors. The study is divided into 3 parts. Part A will enroll subjects with advanced solid tumors of any histology to describe the preliminary safety profile of OR2805 and determine the recommended phase 2 dose (RP2D) of OR2805 alone and in combination with an anti-PD-1 monoclonal antibody. Part B will further characterize the safety and preliminary antitumor activity of OR2805 either alone or in combination with an anti-PD-1 or chemotherapy in previously treated non-small cell lung cancer (NSCLC), melanoma and liposarcoma, as well as in previously untreated NSCLC in combination with an anti-PD-1 antibody. Part C will evaluate OR2805 monotherapy in relapsed squamous cell carcinoma of the head and neck and other tumor types with an emphasis on correlative biomarker analysis. OR2805 will be infused on Day 1 of 21-day cycles. Primary endpoints are adverse events, laboratory abnormalities, dose-limiting toxicities, and dose-level safety and activity. Secondary endpoints are objective response rates, duration of response, complete response, progression-free survival, overall survival, PK, and antidrug antibodies. Exploratory biomarkers of OR2805-mediated pharmacodynamic effects and immune stimulation will be explored. The study was opened September 2021 and is enrolling at sites in the United States with planned expansion within the US and to Europe. Clinical trial information: Clinical trial information: NCT05094804." @default.
• W4286294911 created "2022-07-21" @default.
• W4286294911 creator A5038268549 @default.
• W4286294911 creator A5051923080 @default.
• W4286294911 creator A5060992997 @default.
• W4286294911 creator A5069690249 @default.
• W4286294911 creator A5082674870 @default.
• W4286294911 creator A5086980150 @default.
• W4286294911 date "2022-06-01" @default.
• W4286294911 modified "2023-09-28" @default.
• W4286294911 title "A phase 1/2 dose escalation/expansion study of OR2805 alone or in combination in subjects with advanced solid tumors." @default.
• W4286294911 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps2693" @default.
• W4286294911 hasPublicationYear "2022" @default.
• W4286294911 type Work @default.
• W4286294911 citedByCount "1" @default.
• W4286294911 countsByYear W42862949112022 @default.
• W4286294911 crossrefType "journal-article" @default.
• W4286294911 hasAuthorship W4286294911A5038268549 @default.
• W4286294911 hasAuthorship W4286294911A5051923080 @default.
• W4286294911 hasAuthorship W4286294911A5060992997 @default.
• W4286294911 hasAuthorship W4286294911A5069690249 @default.
• W4286294911 hasAuthorship W4286294911A5082674870 @default.
• W4286294911 hasAuthorship W4286294911A5086980150 @default.
• W4286294911 hasConcept C126322002 @default.
• W4286294911 hasConcept C159654299 @default.
• W4286294911 hasConcept C197934379 @default.
• W4286294911 hasConcept C202751555 @default.
• W4286294911 hasConcept C203014093 @default.
• W4286294911 hasConcept C2775858924 @default.
• W4286294911 hasConcept C2776146153 @default.
• W4286294911 hasConcept C2776999253 @default.
• W4286294911 hasConcept C2777701055 @default.
• W4286294911 hasConcept C2778375690 @default.
• W4286294911 hasConcept C2779244956 @default.
• W4286294911 hasConcept C502942594 @default.
• W4286294911 hasConcept C542903549 @default.
• W4286294911 hasConcept C55493867 @default.
• W4286294911 hasConcept C71924100 @default.
• W4286294911 hasConcept C86803240 @default.
• W4286294911 hasConcept C8891405 @default.
• W4286294911 hasConcept C98274493 @default.
• W4286294911 hasConceptScore W4286294911C126322002 @default.
• W4286294911 hasConceptScore W4286294911C159654299 @default.
• W4286294911 hasConceptScore W4286294911C197934379 @default.
• W4286294911 hasConceptScore W4286294911C202751555 @default.
• W4286294911 hasConceptScore W4286294911C203014093 @default.
• W4286294911 hasConceptScore W4286294911C2775858924 @default.
• W4286294911 hasConceptScore W4286294911C2776146153 @default.
• W4286294911 hasConceptScore W4286294911C2776999253 @default.
• W4286294911 hasConceptScore W4286294911C2777701055 @default.
• W4286294911 hasConceptScore W4286294911C2778375690 @default.
• W4286294911 hasConceptScore W4286294911C2779244956 @default.
• W4286294911 hasConceptScore W4286294911C502942594 @default.
• W4286294911 hasConceptScore W4286294911C542903549 @default.
• W4286294911 hasConceptScore W4286294911C55493867 @default.
• W4286294911 hasConceptScore W4286294911C71924100 @default.
• W4286294911 hasConceptScore W4286294911C86803240 @default.
• W4286294911 hasConceptScore W4286294911C8891405 @default.
• W4286294911 hasConceptScore W4286294911C98274493 @default.
• W4286294911 hasIssue "16_suppl" @default.
• W4286294911 hasLocation W42862949111 @default.
• W4286294911 hasOpenAccess W4286294911 @default.
• W4286294911 hasPrimaryLocation W42862949111 @default.
• W4286294911 hasRelatedWork W1572283981 @default.
• W4286294911 hasRelatedWork W1612226940 @default.
• W4286294911 hasRelatedWork W1996150995 @default.
• W4286294911 hasRelatedWork W2001861465 @default.
• W4286294911 hasRelatedWork W2016479862 @default.
• W4286294911 hasRelatedWork W2023771859 @default.
• W4286294911 hasRelatedWork W2380021556 @default.
• W4286294911 hasRelatedWork W2402960538 @default.
• W4286294911 hasRelatedWork W2984962695 @default.
• W4286294911 hasRelatedWork W3048051248 @default.
• W4286294911 hasVolume "40" @default.
• W4286294911 isParatext "false" @default.
• W4286294911 isRetracted "false" @default.
• W4286294911 workType "article" @default.